📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response. (2023)

First Author: Ladhani SN

Attributed to: Phase 1 COVID-19 Immunity - National Core Study funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(23)00270-0

PubMed Identifier: 37336224

Publication URI: http://europepmc.org/abstract/MED/37336224

Type: Journal Article/Review

Volume: 23

Parent Publication: The Lancet. Infectious diseases

Issue: 9

ISSN: 1473-3099